These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6174742)

  • 1. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer.
    Horning SJ; Levine JF; Miller RA; Rosenberg SA; Merigan TC
    JAMA; 1982 Mar; 247(12):1718-22. PubMed ID: 6174742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients.
    Sherwin SA; Knost JA; Fein S; Abrams PG; Foon KA; Ochs JJ; Schoenberger C; Maluish AE; Oldham RK
    JAMA; 1982 Nov; 248(19):2461-6. PubMed ID: 6752447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients.
    Lucero MA; Magdelenat H; Fridman WH; Pouillart P; Billardon C; Billiau A; Cantell K; Falcoff E
    Eur J Cancer Clin Oncol; 1982 Mar; 18(3):243-51. PubMed ID: 6178592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.
    Gutterman JU; Fine S; Quesada J; Horning SJ; Levine JF; Alexanian R; Bernhardt L; Kramer M; Spiegel H; Colburn W; Trown P; Merigan T; Dziewanowski Z
    Ann Intern Med; 1982 May; 96(5):549-56. PubMed ID: 6176159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon and spontaneous cytotoxicity in man. II. Studies in patients receiving exogenous leukocyte interferon.
    Einhorn S; Blomgren H; Strander H
    Acta Med Scand; 1978; 204(6):477-83. PubMed ID: 282781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in a intermittent schedule in cancer patients.
    Quesada JR; Gutterman JU
    J Natl Cancer Inst; 1983 Jun; 70(6):1041-6. PubMed ID: 6190033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial.
    Sherwin SA; Mayer D; Ochs JJ; Abrams PG; Knost JA; Foon KA; Fein S; Oldham RK
    Ann Intern Med; 1983 May; 98(5 Pt 1):598-602. PubMed ID: 6342490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical toxicity of interferons in cancer patients: a review.
    Quesada JR; Talpaz M; Rios A; Kurzrock R; Gutterman JU
    J Clin Oncol; 1986 Feb; 4(2):234-43. PubMed ID: 2418169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in the expression of a beta 2-microglobulin epitope on hepatocytes in chronic type C hepatitis on treatment with interferon.
    García-Buey L; López-Botet M; García-Sánchez A; Balboa MA; Aramburu J; García-Monzón C; Acevedo A; Moreno-Otero R
    Hepatology; 1993 Mar; 17(3):372-82. PubMed ID: 7680330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
    Maluish AE; Ortaldo JR; Conlon JC; Sherwin SA; Leavitt R; Strong DM; Weirnik P; Oldham RK; Herberman RB
    J Immunol; 1983 Jul; 131(1):503-7. PubMed ID: 6863923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced expression of HLA antigens and beta 2-microglobulin on interferon-treated human lymphoid cells.
    Fellous M; Kamoun M; Gresser I; Bono R
    Eur J Immunol; 1979 Jun; 9(6):446-9. PubMed ID: 91516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon and spontaneous cytotoxicity in man. V. Enhancement of spontaneous cytotoxicity in patients receiving human leukocyte interferon.
    Einhorn S; Blomgren H; Strander H
    Int J Cancer; 1980 Oct; 26(4):419-28. PubMed ID: 6166575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial.
    Borden EC; Holland JF; Dao TL; Gutterman JU; Wiener L; Chang YC; Patel J
    Ann Intern Med; 1982 Jul; 97(1):1-6. PubMed ID: 6178335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion.
    Vadhan-Raj S; Nathan CF; Sherwin SA; Oettgen HF; Krown SE
    Cancer Treat Rep; 1986 May; 70(5):609-14. PubMed ID: 3085930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of various interferons on the spontaneous cytotoxicity exerted by lymphocytes from normal and tumor-bearing patients.
    Lucero MA; Fridman WH; Provost MA; Billardon C; Pouillart P; Dumont J; Falcoff E
    Cancer Res; 1981 Jan; 41(1):294-9. PubMed ID: 6160906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
    Edwards BS; Hawkins MJ; Borden EC
    Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of human leukocyte interferon in patients with advanced cancer.
    Horning SJ; Levine JF; Meyer M; Merigan TC; Rosenberg SA
    J Biol Response Mod; 1983; 2(1):47-56. PubMed ID: 6196450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for the medical use of interferon in 1984.
    Postic B; Arroyo JC
    Henry Ford Hosp Med J; 1984; 32(2):116-22. PubMed ID: 6210270
    [No Abstract]   [Full Text] [Related]  

  • 19. Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease.
    Priestman TJ
    Lancet; 1980 Jul; 2(8186):113-8. PubMed ID: 6157064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.